CUBE vs IBRX · P/E 25, rev $1.07B vs rev $113.3M
CubeSmart (CUBE) versus Immunitybio Inc (IBRX) — a side-by-side from cached financials, not a winner call.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Latest reported IBRX revenue for 2025-12-31 was $113.3M. Net income was -$351.4M. Revenue was up 668.3% from 2024-12-31 to 2025-12-31. IBRX currently screens at market cap $7.88B.
CUBE currently screens at market cap $9.69B and trailing P/E 25.0. IBRX currently screens at market cap $7.88B.
Not investment advice. Open the CUBE and IBRX stock pages for the full models.
Not investment advice.